| Followers | 1 |
| Posts | 430 |
| Boards Moderated | 0 |
| Alias Born | 12/14/2024 |
Friday, April 25, 2025 3:11:53 PM
I don't. Much different process, and I'm not a regulatory professional on either side of the pond. I can offer these thoughts:
1) An early rejection would be for some kind of major issue with the application. The FDA's complete response letters that you usually see are related to manufacturing issues, which is one area where NWBO shareholders are digging up plenty of positive signals on. It "feels" weird to me that an application would be considered this long and then could be rejected outright. So I am not expecting that to happen.
2) I cannot recall a time where I saw a company withdraw their application for approval. I've seen accelerated approval NDAs be pulled when a confirmatory trial failed, but that's a different matter. I highly, highly doubt NWBO will withdraw their application, regardless of what they might be thinking about the status of the review.
Answers are coming soon enough one way or the other.
1) An early rejection would be for some kind of major issue with the application. The FDA's complete response letters that you usually see are related to manufacturing issues, which is one area where NWBO shareholders are digging up plenty of positive signals on. It "feels" weird to me that an application would be considered this long and then could be rejected outright. So I am not expecting that to happen.
2) I cannot recall a time where I saw a company withdraw their application for approval. I've seen accelerated approval NDAs be pulled when a confirmatory trial failed, but that's a different matter. I highly, highly doubt NWBO will withdraw their application, regardless of what they might be thinking about the status of the review.
Answers are coming soon enough one way or the other.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
